Advertisement

Commentary on: Long noncoding RNA DLEU2 regulates the progression of Wilm's tumor via miR-539-3p/HOXB2 axis

Published:September 23, 2022DOI:https://doi.org/10.1016/j.jpurol.2022.08.026
      Yong et al. methodically evaluated the role of the long noncoding RNA (lncRNA) DLEU2/miR-529-3p/HOXB2 axis in Wilm's tumor pathogenesis [
      • Yong J.
      • He J.
      • Ning F.
      Long noncoding RNA DLEU2 regulates the progression of Wilm's tumor via miR-539-3p/HOXB2 axis.
      ]. Through a set of nicely designed experimental studies, the investigators examined the expression of the novel lncRNA DLEU2 in primary Wilm's tumor tissue, Wilm's tumor cell lines, and a xenograft model, and evaluated its regulation by the microRNA miR-539-3p and involvement in expression of the oncogene HOXB2. While previously found to have relevance in other malignancies, this is the first comprehensive evaluation of the expression of these nucleotides with Wilm's tumor progression. DLEU2 impacted cell viability, proliferation, and cell migration in Wilm's tumor cell lines. Through silencing mechanisms, the investigators identified miR-539-3P as a downstream target inhibiting DLEUC2 expression; and that HOXB2, regulated by miR-539-3P, was able to restore the tumorigenic potential of DLEU2. The execution of their studies, use of multiple modalities, and straightforward methodology make this paper easy to follow and accessible to a wide reader audience. The science and results are compelling. It is a nice example of signaling pathway analysis and certainly supports the potential role for targeting lncRNAs, like DLEU2, in the pathogenesis of Wilm's tumors.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Pediatric Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Yong J.
        • He J.
        • Ning F.
        Long noncoding RNA DLEU2 regulates the progression of Wilm's tumor via miR-539-3p/HOXB2 axis.
        J Pediatr Urol. 2022; (In press)
        • Winkle M.
        • El-Daly S.M.
        • Fabbri M.
        • Calin G.A.
        Noncoding RNA therapeutics – challenges and potential solutions.
        Nat Rev Drug Discov. 2021; 20: 629-651
        • Al-Zaidy S.A.
        • Mendell J.R.
        From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA Type 1.
        Pediatr Neurol. 2019; 100: 3-11
        • Scott L.J.
        • Keam S.J.
        Lumasiran: first approval.
        Drugs. 2021; 81: 277-282

      Linked Article